シンバスタチン局所徐放による前十字靭帯再建術後の移植腱-骨孔間の成熟促進効果について by Oka, Shinya
Kobe University Repository : Thesis
学位論文題目
Title
Local Administration of Low-Dose Simvastatin-
Conjugated Gelatin Hydrogel for Tendon-Bone Healing in
Anterior Cruciate Ligament Reconstruction
氏名
Author Oka, Shinya
専攻分野
Degree 博士（医学）
学位授与の日付
Date of Degree 2013-09-25
公開日
Date of Publication 2014-09-01
Resource Type Thesis or Dissertation / 学位論文
報告番号
Report Number 甲第5917号
URL http://www.lib.kobe-u.ac.jp/handle_kernel/D1005917
※当コンテンツは神戸大学の学術成果です。無断複製・不正使用等を禁じます。
著作権法で認められている範囲内で、適切にご利用ください。
Create Date: 2016-06-16
Local Administration of Low-Dose Simvastatin-Conjugated
Gelatin Hydrogel for Tendon–Bone Healing in Anterior
Cruciate Ligament Reconstruction
Shinya Oka, MD,1 Tomoyuki Matsumoto, MD, PhD,1 Seiji Kubo, MD, PhD,1 Takehiko Matsushita, MD, PhD,1
Hiroshi Sasaki, MD, PhD,1 Yuichiro Nishizawa, MD,1 Tokio Matsuzaki, MD,1 Takashi Saito, MS,2
Kotaro Nishida, MD, PhD,1 Yasuhiko Tabata, PhD, DMedSci, DPharm,2
Masahiro Kurosaka, MD, PhD,1 and Ryosuke Kuroda, MD, PhD1
Anterior cruciate ligament (ACL) reconstruction with the hamstring tendon graft takes a long time, as the tendon
graft needs to heal at the site of the bone–tendon integration in the created bone tunnels. Several reports have
shown the therapeutic effects of simvastatin on bone formation with neovascularization. The aim of this study
was to test the hypothesis that enhanced angiogenesis and osteogenesis by locally applied simvastatin promotes
tendon–bone healing after ACL reconstruction. Rabbits received ACL reconstruction with hamstring tendon
graft and were implanted with either simvastatin-conjugated gelatin hydrogel or gelatin hydrogel alone in their
bone tunnels, and then bone regeneration and neovascularization at tendon–bone interface and biomechanical
properties were assessed. Histological analysis at week 2 demonstrated that tendon–bone healing was signifi-
cantly greater with angiogenesis and osteogenesis in the simvastatin-treated group than in the control group.
Computed tomography at weeks 2 and 4 showed a significantly smaller tibial bone tunnel in the simvastatin-
treated group. Biomechanical testing at week 2 demonstrated a significant increase in ultimate failure load in the
simvastatin-treated group. This study suggested that local administration of low-dose simvastatin-conjugated
gelatin hydrogel promotes the tendon–bone healing via its effect on both angiogenesis and osteogenesis at an
early phase in a rabbit model, but does not affect biomechanical property in long-term after ACL reconstruction.
Introduction
Anterior cruciate ligament (ACL) injury is one of themost frequent knee-related injuries, which interferes
with sport activities, especially in young athletes. ACL re-
construction has become the gold standard due to its positive
results. In several procedures for ACL reconstruction, ham-
string tendon grafts have been widely used due to reduced
donor-site morbidity compared to bone-patellar tendon–bone
graft.1–6 However, ACL reconstruction with hamstring tendon
graft requires healing at the site of bone–tendon integration in
the created bone tunnels, which takes as long as 9 to 12
months, and is significantly slower than bone-plug graft-to-
bone healing.7–9 In addition, previous animal studies have
revealed that biological acceleration of tendon–bone healing
results in improved mechanical strength. The use of growth
factors, such as bone morphogenetic protein-2 (BMP-2),10,11
transforming growth factor-b1,12 platelet-derived growth fac-
tor,13 granulocyte colony-stimulating factor,14 and hepatocyte
growth factor,15 and mesenchymal stem cells16,17 has been
shown to be effective in improving maturation of the tendon–
bone interface. However, problems due to their complicated
synthesis, financial cost, and biological safety remain, and the
precise dosage for therapeutic use is uncertain.
Simvastatin, an inhibitor of the competitive 3-hydroxy-3-
methyl-glutaryl coenzyme A reductase, is a convenient and
economical drug, which has been widely used to treat hy-
perlipidemia. In recent years, it has been reported that statins
possess pleiotropic effects that include improvement of en-
dothelial effect,18,19 anti-inflammatory effect,20,21 and stimu-
lation of angiogenesis.22,23 Additionally, since Mundy et al.
found that statins could have an anabolic effect on bone
formation both in vitro and in vivo by activating the promoter
of the BMP-2 gene,24 many observations and experiments
investigating the favorable effects of statins on bone forma-
tion have been reported.24–29 In our previous study, Fukui
et al. reported the efficacy of low-dose simvastatin for bone
fracture healing stimulated by enhanced osteogenesis and
angiogenesis.29 Although several reports have shown a cer-
tain therapeutic effect of simvastatin on bone formation with
neovascularization,24,25,27,30 systemic administration of sim-
vastatin minimized these positive effects due to clearance in
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the liver, suggesting the need for high-dose administration
that may then cause systemic adverse side effects.
To overcome the problem of low efficacy/frequent side
effects by high doses of simvastatin treatment, we utilized
biodegradable gelatin hydrogels as a tool for drug delivery
for tendon–bone healing in ACL reconstruction. We aimed to
test the hypothesis that enhanced angiogenesis and osteo-
genesis by local administration of low-dose simvastatin-
conjugated gelatin hydrogel promote tendon–bone healing
after ACL reconstruction.
Materials and Methods
Gelatin hydrogel
Simvastatin was provided by Merck & Co., Inc. The pro-
cedure for producing simvastatin-conjugated gelatin hydro-
gel has been described previously.28,29 Briefly, in the first
step, l-lactic acid oligomer (LAo) with a number average
molecular weight of 1000 was synthesized from an l-lactide
monomer by ring opening polymerization with the stannous
octate of catalyst and 2-(2-methoxy-ethoxy)ethanol as an
initiator. By activating the hydroxyl groups of LAo and
mixing that with a gelatin solution, LAo-grafted gelatin was
synthesized. The simvastatin solution was added to the LAo-
grafted gelatin solution. The reaction mixture was dialyzed
and then freeze-dried to obtain simvastatin water-solubilized
by LAo-grafted gelatin micelles (statin–micelle). Simvastatin-
conjugated gelatin hydrogels were prepared through the
chemical crosslinking of gelatin with glutaraldehyde ac-
cording to the method described previously.28 The hydrogel
sheets were cut into small squares for use in the study. The
gelatin hydrogels were designed to biodegrade for an aver-
age of *3 weeks in an in vivo condition. Similarly, empty
gelatin hydrogels without simvastatin were prepared as
controls.
Surgical procedures
This animal experiment was approved by the Institutional
Animal Care and Use Committee of Kobe University. Forty-
two skeletally mature Japanese White Rabbits (Kitayama
Labs) weighing between 3.0 and 3.5 kg were used in this
study. All animals underwent bilateral ACL reconstruction
under general anesthesia with an intravenous pentobarbital
sodium solution (Kyoritsu-seiyaku, 30 mg/kg body weight).
The bilateral limbs were disinfected before skin incisions
were made. After subcutaneous injection of 3 mL of 1% li-
docaine, the medial parapatellar approach was used to ex-
pose the knee joint. The native ACL was exposed and
completely transected. The bone tunnels were created with
the use of a 2.5-mm-diameter drill in the femur and tibia
referred to as the insertion of the native ACL. An ipsilateral
semitendinosus tendon was harvested as a graft, and gelatin
hydrogel was wrapped by the tendon graft as much as
possible not to disturb tendon–bone healing. The tendon
graft with gelatin hydrogel was advanced though the tunnel.
The amount of simvastatin applied to each bone tunnel was
125 mg in both femur and tibial bone tunnels. A total of
250 mg of gelatin hydrogel incorporating simvastatin was
implanted in the right knees, and the gelatin hydrogel alone
was implanted into the bone tunnels in the left knees to serve
as the control group (Fig. 1). The dose of simvastatin was
determined by a previous study assessing the effect on os-
teogenesis and angiogenesis.29 The end of the graft was su-
tured at manual maximum tension to the periosteum and
surrounding soft tissue using 4-0 Ethibond sutures (Ethicon,
Inc.) at 90 of knee flexion. The retinacular incision and
wound were closed in layers with 3-0 nylon sutures (Alfresa
Co.). Postoperatively, the animals were then returned to their
cages and permitted to bear full weight.
Each animal was sacrificed with the lethal injection of
pentobarbital at either 2, 4, or 8 weeks after surgery for
FIG. 1. Surgical procedure of
anterior cruciate ligament (ACL)
reconstruction in this study. The
hamstring tendon graft was passed
though the bone tunnel. The
proximal and distal ends of the
graft were fixed to the periosteum
using 4-0 Ethibond sutures. The
gelatin hydrogels were implanted
into both bone tunnels. Color
images available online at
www.liebertpub.com/tea
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assessment: 21 rabbits for the histological assessment, 18
rabbits for the biomechanical assessments, and 3 rabbits
treated with bevacizumab (Table 1).
Histology
Immediately after sacrifice, the specimens were fixed in 4%
paraformaldehyde in 0.1 M phosphate-buffered saline (PBS)
for 24 h. After each sample had been decalcified in 10% ethy-
lenediaminetetraacetic acid with PBS at room temperature for
2 weeks, it was dehydrated with a graded alcohol solution and
embedded in paraffin wax. The samples were sectioned par-
allel to the longitudinal axis of the tibial tunnel. For conven-
tional light microscopy, sections were cut at 5mm and stained
with hematoxylin and eosin. Russell-Movat pentachrome stain
was also performed to see the tendon–bone interface with light
microscopy (n=5, at each group at each time point).
Immunohistochemical staining
for evaluating angiogenesis
To assess angiogenesis at the tendon–bone interface, sec-
tions were prepared from paraffin-embedded samples at
week 2 (n = 5 at each group). Immunohistochemical staining
for isolectin B4 (Vector Laboratories) as an endothelial cell
marker was visualized with fluorescence, and the capillary
density was morphometrically evaluated as the average va-
lue in five randomly selected fields (250mm· 250 mm) of the
tendon–bone interface from each animal. Capillaries were
recognized as tubular structures positive for isolectin B4. The
two investigators performing immunohistochemical analysis
were blinded to the animal treatment.
Immunohistochemical staining
for evaluating osteogenesis
To analyze osteogenesis at the tendon–bone interface, os-
teocalcin was immunohistochemically stained (n = 5 at each
group). Briefly, sections were deparaffinized according to the
standard procedures. Sections were treated with proteinase
K (S3020; Dako) for 10 min at 37C. Primary mouse anti-
osteocalcin monoclonal antibody (Thermo Scientific) diluted
1:200 in a CanGet Signal immunoreaction enhancer solution
(TOYOBO) was placed on the section overnight at 4C. Slides
were washed with PBS after incubation for 2 h at room
temperature with a fluorescent-labeled goat anti-mouse sec-
ondary antibody (Alexa Fluor 546 goat anti-mouse IgG)
diluted 1:500 (4 mg/mL) in a CAN GET SIGNAL im-
munoreaction enhancer solution.
Bone tunnel evaluation by micro-CT
The femur–ACL graft–tibia complex (n = 6 at each group at
each time point), with a femur length of 45 mm and a tibia
length of 60 mm, was harvested from each knee immediately
after sacrifice and frozen at - 30C until testing. Before
testing, the specimen was thawed overnight at room tem-
perature. The areas of the vertical plane of the axis of the
bone tunnel at 5-mm depth from the tibial joint surface were
measured using microcomputed tomography (micro-CT,
250-mm slice thickness; ALOKA LaTheta Laboratory CT).
The areas were estimated with image analysis software
(ImageJ; National Institutes of Health). The areas were
measured an average of three times.
Biomechanical study
After measuring the area of the bone tunnel, the biome-
chanical study was performed (n = 6 for each group at each
time point). All soft tissue, except for the ACL graft, was
removed by sharp dissection. The knee was potted at 45 of
flexion with the bone tunnel oriented parallel to the testing
axis (Fig. 2). All mechanical testing was conducted using a
tensile sensor (AG-I SHIMAZU Co.). Before the tensile test
Table 1. Organization of the Experiment
Week 2 Week 4 Week 8
Histology
Hematoxylin and eosin stain 5 5 5
Russell-Movat pentachrome
stain
5 5 5
Assessment of angiogenesis
Capillary density 5 - -
VEGF expression 6 - -
Inhibition of
neovascularization
6 - -
Assessment of osteogenesis
Osteoblast density 5 - -
Bone tunnel evaluation
by micro-CT
6 6 6
Biomechanical testing
Failure load 6 6 6
Stiffness 6 6 6
The figures are expressed number of experimental animal.
FIG. 2. The specimen was fixed and oriented for tensile
testing, so the pullout loads were applied with the knee at
45 of flexion. Color images available online at www
.liebertpub.com/tea
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was conducted, preloading of 1N for 1 min and cyclic pre-
conditioning of the constructs between elongation limits of 0
and 0.75 mm were applied. Immediately after precondition-
ing, the ultimate load to failure (N) was recorded in uniaxial
tension at 10 mm per minute. The stiffness (N/mm) was
calculated from the slope of the linear region of the load-
deformation curve.
Real-time polymerase chain reaction analysis
Immediately after sacrifice at week 2, bone–tendon inter-
face samples (the bone tunnel and its surrounding tissue)
were extracted as cylindrically shaped pieces 3.5 mm in di-
ameter using the Mosaicplasty kit (ACUFEX; MosaicPlasty
Precision, Smith & Nephew) and frozen in liquid nitrogen
(n = 6 for each group). The tissues were homogenized in
TRIzol reagent (Invitrogen) with a T-18 ULTRA-TURRAX
homogenizer (IKA Werke) immediately after the harvest.
Total cellular RNA was extracted from the harvested tissue
using the acid guanidinium thiocyanate–phenol–chloroform
method. After the RNA extraction, RNA was cleaned up
using the RNeasy Mini Kit (Qiagen). mRNA transcription (in
duplicate) was quantified using the Applied Biosystems
StepOne Real-time polymerase chain reaction (RT-PCR)
System (Applied Biosystems). RT-PCR reactions (20 mL)
contained 0.1 mM forward primer, 0.1 mM reverse primer, and
1 mL of cDNA template from RT reaction, and 12.5 mL 10·
Master Mix for Power SYBR green master mix (Applied
Biosystems). Reaction conditions were as follows: 10 min at
95C, followed by 40 cycles at 95C (15 s), and 60C for 1 min.
The level of each target gene was normalized to the levels
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, a
housekeeping gene) and expressed relative to the levels of
the control group at each timepoint (DDCT methods; Ap-
plied Biosystems). All primers used in this study were
mRNA specific (on different exons and crossing over to in-
trons) and designed for RT-PCR analysis of gene expression
using Primer 3 and Primer designing tool (NCBI). Primers
for GAPDH were designed to the forward sequence 5¢-
CCACCTTGTGAAGCTCATTTCCT- 3¢ and the reverse se-
quence 5¢-TCGTCCTCCTCTGGTGCTCT- 3¢. Primers for
vascular endothelial growth factor (VEGF) were designed to
the forward sequence 5¢-CCTTGCCTTGCTGCTCTACC-3¢
and the reverse sequence 5¢-AGGTTTGATCCGCATGAT
CTG-3¢. All primers were obtained from Invitrogen.
Inhibition of neovascularization
To investigate the hypothesis that neovascularization is
essential for tendon–bone healing, we used an anti-VEGF
monoclonal antibody, bevacizumab (Avastin; Genentech,
Inc.). Three rabbits subjected to ACL reconstruction with
simvastatin were intravenously administered 100 mg bev-
acizumab at postoperative day 3.31 At postoperative 2 weeks,
biomechanical assessment and bone tunnel evaluation by
micro-CT were performed.
Statistical analysis
All values were expressed as mean– SEM. The biome-
chanical property, capillary density, osteoblast density, and
expression of VEGF between control groups and simvastatin-
treated groups were compared using Student’s t-tests. The
inhibition of neovascularization was statistically analyzed
using analysis of variance, followed by post-hoc testing with a
Tukey procedure. A probability value < 0.05 was considered
significant.
Results
Histological assessment
Specimens at 2 weeks. There was a less-organized fi-
brous tissue and a very little new bone formation containing
chondroid cells between the edge of the trabecular bone and
the tendon in the control group at week 2 (Fig. 3A and 3B). In
the simvastatin-treated groups, there was aligned connective
tissue, newly formed woven bone, and cartilage in the
tendon–bone interface.
Specimens at 4 weeks. The fibrous connective tissue
was aligned, and the woven bone covered the edge of the
trabeculae between tendon and bone in both groups. There
was more aligned chondroid-like cell and matured interface
in the simvastatin-treated group than in the control group.
The collagen fiber anchored toward the woven bone and
integrated along the tendon was more advanced in the
simvastatin treatment group.
Specimens at 8 weeks. The fibrous connective tissue at
the tendon–bone interface was narrow and unclear in both
groups. A more aligned and layered cartilage zone was ob-
served that incorporated the adjacent bone and tendon in the
simvastatin treatment group.
Assessment of osteogenesis and angiogenesis
Endothelial cells staining with isolectin B4 in tissue samples
collected 2 weeks after surgery revealed enhanced angiogen-
esis in the area of tendon–bone integration in the simvastatin-
treated group. Neovascularization assessed by the capillary
density was significantly increased in the simvastatin-treated
group than in the control group (statin, 112.0– 6.9 vs. control,
72.0– 5.8/mm2; p< 0.01, n= 5) (Fig. 4). Osteoblast stained with
anti-mouse osteocalcin in tissue samples collected 2 weeks
after surgery also revealed augmentation of osteogenesis in
the area of new bone formation in the simvastatin-treated
group. Osteogenesis assessed by osteoblast density was sig-
nificantly enhanced in the simvastatin-treated group com-
pared with the control group (simvastatin, 495.3– 32.9 vs.
control, 272.0– 28.3/mm2; p< 0.001, n= 5) (Fig. 5).
Bone tunnel evaluation
The averages of the bone tunnel area in the simvastatin-
treated group were significantly smaller than in the control
group at weeks 2 and 4 (week 2: simvastatin, 3.25 – 0.33 vs.
control, 4.13 – 0.28/mm2; p< 0.05, n= 6; week 4: simvastatin,
1.61–0.14 vs. control, 2.71–0.31/mm2; p<0.01, n=6) (Fig. 6A
and 6B). At week 8, the averages of the bone tunnel area showed
no significant differences between the two groups (simvastatin,
0.94–0.03 vs. control, 1.61–0.14/mm2; p=0.06, n=6).
Biomechanical testing
The average load to failure in the simvastatin-treated
group was significantly greater than in the control group at
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week 2 (simvastatin, 32.5 – 2.3 vs. control, 21.6 – 3.8 N; p <
0.05, n= 6). At weeks 4 and 8, there were no significant dif-
ferences in the average load to failure between the two
groups (week 4: simvastatin, 35.5 – 1.6 vs. control, 33.4 –
3.5 N; p= 0.68, n= 6; week 8: simvastatin, 38.4– 6.8 vs. control,
36.7– 2.3 N; p= 0.73, n= 6) (Fig. 7A). There were no significant
differences in stiffness between the two groups at each time
point (week 2: simvastatin, 12.8– 1.6 vs. control, 8.9– 2.1 N/m;
p= 0.22, n= 6; week 4: simvastatin, 13.6– 1.2 vs. control,
11.1– 2.9 N/m; p= 0.43, n= 6; week 8: simvastatin, 16.3– 3.8
vs. control, 15.3– 1.5 N/m; p= 0.76, n= 6) (Fig. 7B).
As the assessment of failure mode, five grafts in the con-
trol group and two grafts in the simvastatin-treated group
failed by totally pullout from the bone tunnel, and one graft
in the control group and four grafts in the simvastatin-
treated group were torn-off inside the bone tunnel at week 2.
Two were torn-off inside the bone tunnel, and the others
failed at midsubstance in both groups at weeks 4 and 8.
RT-PCR analysis
At week 2, the simvastatin-treated group showed signifi-
cantly higher VEGF gene expression than the control group
(control group 1.000– 0.192; simvastatin group 1.738– 0.216;
p< 0.05) (Fig. 8).
Inhibition of neovasularization
The average bone tunnel area was significantly larger
in the bevacizumab-injected group than in the control
and simvastatin-treated groups at week 2 (simvastatin,
3.25 – 0.33 vs. control, 4.13 – 0.28 vs. bevacizumab, 5.15 –
0.25/mm2, respectively p < 0.01, n = 6) (Fig. 9).The average
load to failure and stiffness in the bevacizumab-injected
group were significantly lower than in the simvastatin-
treated group (failure load; simvastatin, 32.5 – 2.3 vs. con-
trol, 21.6 – 3.8 vs. bevacizumab, 21.5 – 2.9 N, respectively,
p < 0.05, n = 6; stiffness; simvastatin, 12.8 – 1.6 vs. control,
8.9 – 2.1 vs. bevacizumab, 6.3 – 0.8 N/m; respectively,
p < 0.05, n = 6).
Discussion
In the present study, we elucidated the effectiveness of
low-dose simvastatin-incorporated gelatin hydrogel for
FIG. 3. Histological
evaluation of the tendon–
bone interface of a specimen
from each group at 2, 4, and 8
weeks after surgery (A: H-E
stain; magnification, · 200. B:
R-M stain; magnification,
· 200). In the simvastatin
group, more newly formed
bone and fewer inflammatory
cells were seen in the
interface at week 2 (asterisk).
More aligned chondroid cells
(stained blue) and
perpendicular fibers
connecting the tendon to
bone existed in the
simvastatin group at weeks 4
and 8 in R-M stain
(arrowheads and number
sign). Color images available
online at www.liebertpub
.com/tea
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early tendon–bone healing in ACL reconstruction using a
rabbit model. Histological, radiological, and biomechanical
assessment at the site of the tendon–bone interface provided
early and strong healing. This is the first reported study
demonstrating a therapeutic strategy using simvastatin for
ACL reconstruction surgery.
Reconstructed tendon grafts in the bone tunnels are sep-
arated from their vascular supply; therefore, the ingrowth of
new blood vessels is an essential step in the process of ten-
don graft remodeling. In addition, neovascularization is es-
sential for bone regeneration around the tendon graft and
tissue regeneration at the tendon–bone junction.14,32–34 Wang
et al. applied an extracorporeal shockwave after ACL re-
construction in a dog model and demonstrated that angio-
genesis was essential for tendon–bone healing by detecting
strong VEGF expression in the tendon–bone junction.34 In
the meantime, the positive effects of simvastatin on VEGF
release during wound healing using diabetic mice were also
reported.23 In addition, Kanazawa et al. reported that VEGF
is highly expressed at postoperative week 2 in an in vivo ACL
reconstruction animal model.35 These studies supported our
findings that neovascularization and increased VEGF ex-
pression at the tendon–bone interface promoted by simvas-
tatin were demonstrated in the 2-week specimens.
Endothelial progenitor cells (EPCs) were recognized to re-
spond to tissue ischemia and injury as well as cytokines by
mobilizing the bone marrow into the peripheral blood, mi-
grating to regions of neovascularization to differentiate into
mature endothelial cells, and further promote vasculogen-
esis.36 Among the various cytokines and drugs, statins were
also reported to promote the proliferation, migration, and
survival of endothelial cells and bone marrow-derived EPCs,
FIG. 5. Histological analysis of the tendon–bone interface.
Representative fluorescent vascular staining for osteocalcin
(OC) in the 2-week specimens in the control and simvastatin
group (magnification, · 200). Osteoblasts are indicated in red,
and the average number of osteoblasts was significantly
higher in the simvastatin group than in the control group.
Color images available online at www.liebertpub.com/tea
FIG. 4. Histological analysis of the tendon–bone interface.
Representative fluorescent vascular staining for isolectin B4
(IB4) in 2-week specimens in the control and simvastatin
groups (magnification, · 200). Capillaries are indicated in
green, and the average number of capillaries was signifi-
cantly higher in the simvastatin group than in the control
group. Color images available online at www.liebertpub
.com/tea
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and therefore enhance angiogenesis.37,38 Recently, Fukui et al.
reported that statins induced angiogenesis by increasing
EPCs, and this effect on bone formation contributes to the
improvement of fracture healing using a psuedoarthrosis
model.29 Similarly, in our study, angiogenesis and osteo-
genesis were enhanced by low-dose simvastatin adminis-
tration in the ACL reconstruction model.
Previous studies have shown that osteoinductive agents
accelerated osteointegration to the tendon graft, and os-
teointegration improved the mechanical properties at the
tendon–bone interface.10,11,39 Rodeo et al. reported a nar-
rower interface zone in BMP-treated specimens, indicating
better graft incorporation.10 The current study showed that
histologically simvastatin promoted bone ingrowth into the
tendon–bone interface at week 2 and determined the quan-
tity of the bone tunnel area. Osteocalcin is a well-known
marker of terminal osteoblast differentiation influencing
bone mineralization, and the finding of high osteoblast
density in the simvastatin-treated group also indicated the
effectiveness of simvastatin on osteogenesis. The ultimate
failure load in the simvastatin-treated group was larger than
the control group at 2 weeks, but there were no difference
between the two groups at 4 and 8 weeks. This was because
a consistent regeneration of the direct insertion with a fi-
brocartilage layer at the tendon–bone interface was not ob-
vious at an earlier phase. Tendon–bone healing is classified
into two types: one shows layered chondral formation at
tendon–bone interface that resembles normal ligament–bone
FIG. 6. Micro-CT scans at each group and time point. (A)
The areas of vertical plane of the axis of bone tunnel at a 5-
mm depth from the tibial joint surface were measured with
ImageJ. (B) The mean bone tunnel areas in the simvastatin
group were significantly smaller than in the control group at
2 and 4 weeks. The mean bone tunnel area showed no sig-
nificant difference at 8 weeks. N.S., not significant.
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insertion, and this type mainly plays a role to mechanical
strength; and the other type shows fibrous insertion where
tendon and bone directly come in contact with each other.8
Both types need osteogenesis at the tendon–bone interface.
Fibrous insertion appears at early phase, and layered chon-
dral formation takes a long time to mature and accomplish
higher mechanical strength. The chondral tendon–bone
healing was more seen in the simvastatin-treated group at
weeks 4 and 8, but incompletely matured chondral healing
could not strengthen biomechanical properties. Meanwhile,
fibrous healing where tendon and bone come in contact with
each other was seen in histological findings and bone tunnel
evaluation in the simvastatin-treated group at week 2. That is
why the failure load in the simvastatin-treated group was
significantly greater than in the control group at week 2. The
ACL reconstruction model in the study was used on the
assumption that hamstring tendon grafts were fixed with a
suspensory fixation devise. It is well known that the sus-
pensory fixation devise causes bone tunnel widening after
ACL reconstruction, because the fixation point is farther
away from the aperture than the interference screw, and
micromovement occurs at the tendon–bone interface.40,41 In
this study, mechanical property could not be reinforced by
simvastatin in long term, but simvastatin promoted tendon–
bone healing at early stage, and prompt bone infiltration into
the tendon–bone gap could predict to prevent bone tunnel
enlargement and tension loss of the graft in the bone tunnel.
These could be a ground to encourage quicker rehabilitation
after ACL reconstruction.
In this study, we also demonstrated the important role of
angiogenesis on tendon–bone healing, as intravenously in-
jected antiangiogenetic agent prevented bone formation and
weakened biomechanical properties. The mean bone tunnel
area in the bevacizumab-injected group was less than that in
the simvastatin-treated and control groups. Although the
biomechanical property in the bevacizumab-injected group
was significantly decreased compared to the simvastatin-
treated group, there was no difference between the control
and bevacizumab-injected groups. This was explained by the
fact that there was insufficient bone formation and less
contact at the tendon–bone interface in the 2-week specimens
in the control and the bevacizumab-injected groups.
FIG. 7. The femur–ACL graft–tibia complex (n= 5 at each group at each time point) was used for biomechanical testing
using a tensile sensor. (A) The average load to failure in the simvastatin group was significantly greater than in the control
group at week 2. At weeks 4 and 8, there was no significant difference in the average load to failure between the two groups.
(B) There were no significant differences in stiffness between the two groups at each time point.
FIG. 8. Real-time polymerase chain reaction product. Gly-
ceraldehyde-3-phosphate dehydrogenase (GAPDH) rations
for vascular endothelial growth factor (VEGF). The mRNA
expression in the tibial bone tunnel was compared between
the control and the simvastatin-treated groups. Specimens in
the simvastatin-treated group had significantly increased
VEGF/GAPDH at week 2 (n= 6).
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Bevacizumab totally inhibited the beneficial effects of sim-
vastatin on tendon–bone healing. The results demonstrated
that the positive effect of simvastatin on tendon–bone heal-
ing was associated with increased angiogenesis and osteo-
genesis, whereas an inhibition of VEGF did decrease not only
angiogenesis but also osteogenesis in promoted healing at
the tendon–bone junction. These findings suggest that an-
giogenesis plays a more important role in tendon–bone
healing than osteogenesis.
There are some limitations in this study. Only a single
dose of simvastatin was applied in a small number of ani-
mals. In a future study, a dose–escalation study should be
investigated in a large number of animals to find whether the
treatment is effective in a dose-dependent manner or not.
The results might be some specific effects, so that repeating
the experiment in a larger animal would be worthwhile to
put a practical clinical use. Both hind limbs simultaneously
received ACL reconstruction. To simulate the healing process
in the clinical setting, a one-sided operation should be per-
formed.
In conclusion, the local administration of low-dose
simvastatin-conjugated gelatin hydrogel promotes tendon–
bone healing at an early stage via angiogenesis and osteo-
genesis, but does not affect the biomechanical property in
long term. This convenient and economical method may
enable a new strategy for the promotion of recovery after
ACL reconstruction.
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